← Back to Search

Small Molecule Inhibitor

VMD-928 for Advanced Cancer

Phase 1
Recruiting
Research Sponsored by VM Oncology, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma that is not responsive to standard therapies or had progressed following standard therapy and for which there is no approved or curative therapy
Adequate organ system function
Timeline
Screening 3 weeks
Treatment Varies
Follow Up on day 1 and day 15 of cycle 1 (each cycle is 28 days)
Awards & highlights

Study Summary

This trial is testing a new drug for adults with advanced cancer that has not responded to other treatments.

Who is the study for?
Adults with advanced solid tumors or lymphoma that have no standard curative therapy left. They must have TrkA overexpression, NTRK1 gene fusion, or progression after pan-Trk inhibitor treatment. Participants need to be in good physical condition (ECOG score of 0-1), able to take oral meds, and provide tumor tissue for analysis.Check my eligibility
What is being tested?
The trial is testing VMD-928, an oral medication aimed at treating various cancers by targeting the TrkA protein. It's a Phase 1 study where all participants receive the drug to evaluate its safety and effectiveness against their cancer.See study design
What are the potential side effects?
Specific side effects are not listed here but may include typical reactions related to anticancer medications such as nausea, fatigue, liver issues, changes in blood counts leading to increased infection risk or bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is not responding to standard treatments or has worsened after them.
Select...
My organs are functioning well.
Select...
I am fully active or can carry out light work.
Select...
I can take pills and keep them down.
Select...
My organs are functioning well.
Select...
My tumor shows high TrkA protein levels, has NTRK1 gene changes, or grew after Trk treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~on day 1 and day 15 of cycle 1 (each cycle is 28 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and on day 1 and day 15 of cycle 1 (each cycle is 28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number and severity of treatment-emergent AEs
Secondary outcome measures
Analgesic response as defined by the Brief Pain Inventory (BPI).
Area under the plasma concentration versus time curve (AUC) of VMD-928.
Change in TrkA protein expression.
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

VM Oncology, LLCLead Sponsor
Clinical DevelopmentStudy ChairVM Oncology, LLC
34 Previous Clinical Trials
88,570 Total Patients Enrolled
Peg Fletcher, MD PhDStudy DirectorMedAssessment

Media Library

VMD-928 (Small Molecule Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03556228 — Phase 1
Non-Small Cell Lung Cancer Research Study Groups: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Non-Small Cell Lung Cancer Clinical Trial 2023: VMD-928 Highlights & Side Effects. Trial Name: NCT03556228 — Phase 1
VMD-928 (Small Molecule Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03556228 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the magnitude of participants in this research endeavor?

"To enroll in the trial, 74 patients who meet the pre-set inclusion criteria need to be recruited. They can join from either The University of Texas MD Anderson Cancer Center or Medical College of Wisconsin."

Answered by AI

Are there any open slots for prospective participants in this research?

"Correct. Clinicaltrials.gov reports that this medical experiment is currently recruiting participants, with the original posting taking place on June 8th 2018 and the most recent update made to it on September 28th 2022."

Answered by AI

Has the FDA endorsed VMD-928 300 mg Tablets or 100 mg Capsules?

"The safety of VMD-928 300 mg Tablets or 100 mg Capsules is estimated as a 1 due to its Phase 1 classification, signifying that there are only early signs of efficacy and minimal data supporting safety."

Answered by AI

How many sites are currently implementing this research endeavor?

"The University of Texas MD Anderson Cancer Center in Houston, Medical College of Wisconsin located in Milwaukee, and Weill-Cornell Medicine at Cornell University are the most notable medical sites that this clinical trial is running out of. This along with 7 other locations across the US make up the entire list."

Answered by AI
~12 spots leftby Jun 2025